Concepedia

Keith A. Otto

KA

Statistics

Publications

9

Citations

873

H-Index

9

Active since

1997

Affiliations

Eli Lilly (United States)(Current)

Jubilant Life Sciences (India)

Keith A. Otto is an author at Eli Lilly (United States) specializing in pharmacology, diabetes mellitus, and receptor pharmacology.

Publications per year

1997–2018

9

Publications

9

Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis

Guoqing Cao, Liang Yu, Carol L. Broderick et al. · Journal of Biological Chemistry · 2003 · 293 citations · Full text

, , +17

Molecular determinants of FGF‐21 activity—synergy and cross‐talk with PPARγ signaling

Julie S. Moyers, Tatiyana L. Shiyanova, Farrokh Mehrbod et al. · Journal of Cellular Physiology · 2006 · 187 citations · Full text

, , +17

Deficiency of Adiponectin Receptor 2 Reduces Diet-Induced Insulin Resistance but Promotes Type 2 Diabetes

Yanfang Liu, M. Dodson Michael, Shera Kash et al. · Endocrinology · 2006 · 114 citations

, , +17

Structural basis for GPR40 allosteric agonism and incretin stimulation

Joseph D. Ho, Betty Chau, Logan Rodgers et al. · Nature Communications · 2018 · 85 citations · Full text

, , +17

A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia

Anne Reifel‐Miller, Keith A. Otto, Eric D. Hawkins et al. · Molecular Endocrinology · 2005 · 64 citations · Full text

, , +17

1–5 of 9